Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CVS Health Corporation (NYSE: CVS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission (SEC). These filings document material events, financial results, capital markets transactions, governance changes and legal developments that affect CVS Health and its shareholders.
Among the key documents are current reports on Form 8-K, which CVS Health uses to announce items such as quarterly and year-to-date financial results, updated financial guidance, and Investor Day presentations. For example, the company has filed Form 8-K reports furnishing press releases that discuss strategic priorities, revenue and earnings guidance, and non-GAAP measures like adjusted operating income and adjusted earnings per share, along with reconciliations to GAAP metrics.
Other Form 8-K filings describe governance actions, including the Board of Directors’ appointment of J. David Joyner, President and Chief Executive Officer, to the additional role of Chair of the Board. Capital markets activity is also reflected in filings that detail the issuance of senior notes under an Underwriting Agreement, including principal amounts, maturities, interest rates and references to the governing senior indenture and registration statement.
Filings further address legal and subsidiary matters, such as the disclosure that Omnicare, LLC, a wholly owned indirect subsidiary of CVS Health, and certain of its subsidiary entities voluntarily initiated chapter 11 proceedings under the U.S. Bankruptcy Code to address litigation-related monetary damages and other financial challenges. These documents outline the use of debtor-in-possession financing and the evaluation of restructuring options.
On Stock Titan, AI-powered tools summarize and highlight the contents of CVS Health’s SEC filings, helping readers quickly identify key points in lengthy documents such as 8-Ks, and providing context around financial measures, governance changes and risk-related disclosures.
CVS Health (CVS) reported a Q3 2025 net loss driven by a non-cash impairment. Total revenues rose to $102.871B from $95.428B a year ago, led by higher product sales and premiums. However, a $5.725B goodwill impairment and higher operating costs pushed operating income to a loss of $3.207B versus income of $832M last year. Net loss attributable to CVS Health was $3.975B (diluted EPS -$3.13), compared with net income of $87M (EPS $0.07) in Q3 2024.
Year to date, revenues reached $296.374B, while net income attributable to CVS Health was a loss of $1.175B (EPS -$0.93). The quarter included a $483M gain on the deconsolidation of a subsidiary and $632M of net investment income. Cash from operations for the first nine months was $7.249B, essentially flat year over year. On the balance sheet, cash and cash equivalents were $9.098B, goodwill declined to $85.478B, and total debt (short-term, current portion of long-term, and long-term) remained significant. As of October 22, 2025, shares outstanding were 1,269,432,485.
CVS Health Corporation furnished an update on its financial performance. The company announced results for the three months ended September 30, 2025, and made the related press release available as Exhibit 99.1 under Item 2.02.
The materials are furnished, not filed, under the Exchange Act, which means they are not subject to Section 18 liability and are not incorporated by reference unless specifically stated.
CVS Health reported insider transactions by its EVP and Chief People Officer. The filing shows indirect purchases of common stock held by a trust for the benefit of the officer’s spouse. Reported trades: 35 shares at $56.47 on 09/09/2024, 10 shares at $62.24 on 10/02/2024, and 35 shares at $56.85 on 10/23/2024. The explanation notes the shares were bought at a broker’s discretion for a managed account and were not previously reported due to a broker error.
CVS Health Corp executive Heidi B. Capozzi filed an amended initial ownership report to include common stock held indirectly. The amendment reflects 5 shares of CVS common stock held by a trust for the benefit of her spouse, which had not been reported previously due to a broker error.
CVS Health Corporation reports that its wholly owned indirect subsidiary Omnicare, LLC and certain related entities have voluntarily begun chapter 11 bankruptcy proceedings in the U.S. to address issues arising from recent litigation in the U.S. District Court for the Southern District of New York, where the court imposed what Omnicare describes as excessive monetary damages.
Omnicare plans to use the court-supervised process to handle broader financial challenges in the long-term care pharmacy industry and to consider restructuring options, including a potential standalone restructuring or sale. Omnicare has arranged debtor-in-possession financing with a third party, which, once approved by the court and combined with ongoing operating cash flows, is expected to provide enough liquidity for the Omnicare entities to continue operating while the chapter 11 process proceeds.
Prem S. Shah, EVP and Group President at CVS Health (CVS), surrendered 6,995 shares on 08/31/2025 to satisfy withholding taxes from the vesting and settlement of a restricted stock unit award. The shares were recorded at a price of $73.15 and, after the transaction, Mr. Shah beneficially owned 60,631.677 shares directly. The Form 4 was signed on 09/02/2025 and reflects a routine insider tax-withholding disposition rather than an open-market sale.
Insider transaction: Tilak Mandadi, Executive Vice President and Chief Experience & Technology Officer at CVS Health (CVS), reported a transaction on 08/31/2025 in which 12,834 shares of CVS common stock were disposed at a price of $73.15 per share. The filing states these shares were surrendered to cover withholding taxes upon vesting and settlement of restricted stock units, a routine payroll tax withholding mechanism for equity compensation. Following the transaction Mandadi beneficially owns 63,952 shares directly.
Anne A. Finucane, a director of CVS Health (CVS), reported a sale of company stock that was filed on Form 4. The filing shows a transaction dated 08/20/2025 in which 7,500 shares of Common Stock were disposed of at a reported price of $71.02 per share under transaction code S(1). After the reported sale, the filing lists 22,156 shares beneficially owned indirectly through a trust. The form includes an explanatory note stating the sale was not timely reported due to an administrative error. The document is signed by Anne M. Finucane on 08/29/2025.
CVS Health Corporation: This Form 144 notifies a proposed sale of 7,500 shares of CVS common stock through Merrill Lynch on the NYSE with an aggregate market value of $532,275, scheduled approximately for 08/20/2025. The filer reports that these shares were received as director compensation across multiple grant dates between 2012 and 2022, totaling specific lots of 1,428; 2,222; 1,546; 2,099; and 205 shares. No securities were reported sold in the past three months. The notice includes the standard representation that the selling person does not possess undisclosed material adverse information.
CVS Health Corporation filed an 8-K reporting documentation related to a debt offering process. The filing references an Underwriting Agreement dated August 11, 2025 naming Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the underwriters. The forms of four notes with maturities labeled 2032, 2035, 2055 and 2065 are included as exhibits, along with the opinion and consent of Wachtell, Lipton, Rosen & Katz. The cover page Inline XBRL data is noted as filed. The filing is signed by Brian Newman, Executive Vice President and Chief Financial Officer on August 15, 2025.